Thu, 13 May 2021 03:22:06 +0000
The pre-recorded SNL sketch with the premise 'FOMO Capital' from Elon Musk's hosting week will be released in the future as a digital short (a 'cut for time' online video).
“there was one they recorded, which I think will come out as a digital short, and the premise is FOMO capital” View on YouTube
No verifiable record confirms whether this specific unaired 'FOMO Capital' SNL sketch was ever released as a digital short.
At the point when U.S. interest rates return to their historical average level, the annual federal interest expense on the national debt will consume roughly 30% of the U.S. federal budget.
“when interest rates revert to the norm, the historical norm, interest expense on our debt will be 30% of the government budget” View on YouTube
As interest rates rose substantially from 2022-2024, net interest expense grew to a large and growing share of the federal budget (reported around 13-17% of spending by 2024-2025), a significant increase but not yet at the specific 30% figure predicted.
Given current U.S. policies in mid‑2021 (heavy stimulus, impaired labor force participation, rising input costs, and higher wages), consumer prices in the U.S. will experience significant inflation in the near term relative to the pre‑COVID period.
“we have more taxation. That's also just going to be wasted. So very poor ROI. And then now we have input costs going up, um, and prices going up to try to attract people. It's it's all going to drive price inflation.” View on YouTube
The US did experience significant consumer price inflation in 2021-2022, with CPI peaking around 9% in mid-2022, driven partly by the stimulus, labor, and input-cost dynamics described.
The Biden administration's mid‑2021 fiscal and monetary agenda—characterized by very large spending and tax increases—will backfire over the next few years by undermining the anticipated post‑COVID economic boom (e.g., via higher inflation, higher interest rates, and weaker growth), in a way comparable to the economic disappointment under President Jimmy Carter.
“It's going to backfire. I think it's going to backfire massively.” View on YouTube
The 2021-2022 stimulus era was followed by high inflation and rate hikes that caused real economic pain and a growth slowdown, broadly consistent with 'backfiring,' though the US avoided a deep Carter-era-style stagflationary spiral and inflation was later brought down without a severe recession.
Continuing the then-current mix of elevated unemployment benefits, stimulus, and crypto gains (described as a UBI experiment) will lead to negative or significantly throttled U.S. economic growth because it will reduce labor-force participation.
“We are now running a dry run with cryptocurrency and, you know, stimulus, a UBI experiment. And the result of this UBI experiment is, uh, negative economic growth or a throttled economic growth. We cannot be productive if people don't want to work and contribute.” View on YouTube
The US did not experience negative or severely throttled overall economic growth in the following years; GDP growth remained positive through 2021-2022 despite labor market tightness and elevated unemployment benefits during parts of that period.
Given high fiscal/monetary stimulus, a less-motivated labor force, rising taxes, and rising input and wage costs (as of May 2021), the combined effect will be a notable increase in price inflation in the U.S. in the following period.
“So we have these two opposing forces, right? We have so much stimulus. We have, um, an under-motivated labor force. We have more taxation. That's also just going to be wasted. So very poor ROI. And then now we have input costs going up, um, and prices going up to try to attract people. It's it's all going to drive price inflation.” View on YouTube
The combination of stimulus, labor market tightness, rising input costs, and wage growth did drive a substantial increase in US price inflation through 2021-2022.
If a moderate, centrist political agenda does not gain traction in upcoming election cycles, the U.S. will evolve toward a de facto system of 50 highly balkanized states operating much more independently from each other over the ensuing years.
“Otherwise, we are headed to 50 balkanized states operating independently.” View on YouTube
US political polarization and state-level policy divergence did intensify through the 2020s, though a full de facto 'balkanization' into 50 independently operating states has not occurred; federal cohesion, while strained, persists.
The Zymergen and Ginkgo Bioworks IPOs/SPAC (around early 2021) mark a "Netscape moment" for synthetic biology, leading to a surge of activity—many more companies, technologies, and applications—in synthetic biology over the next few years (roughly 2–5 years after 2021).
“Synthetic biology is this kind of ESG, you know, moment. Um, and and I think these two IPOs happening at the valuations that they're happening at and the capital that's going in, I think these are kind of like the Netscape moments for synthetic biology. And we're going to see a tremendous amount happen over the next couple of years.” View on YouTube
Synthetic biology did see continued investment and activity growth over the following years, though it did not experience a clear 'Netscape moment' surge comparable to the internet boom; the sector grew more gradually and unevenly.
Over the course of the 21st century, synthetic biology will come to fruition as a general-purpose technology that completely reinvents industrial production (materials, food, chemicals, plastics), substantially improves environmental sustainability, and serves as a primary enabler for long-term human sustainability on Earth.
“the premise that everyone believes is going to come to fruition in the century, and it will completely reinvent industry, will improve sustainability. I think it is going to be the great savior for this planet and for our ability to sustain on this planet.” View on YouTube
This is a century-long claim about synthetic biology's ultimate societal impact that cannot be meaningfully evaluated this early.
Pivot Bio, a private synthetic biology company as of May 2021, will go public (via IPO, SPAC, or direct listing) within approximately 3–4 years, i.e., by mid-2024 to mid-2025.
“This is this is a private company. But you know, you'll you'll see them in the next probably 3 or 4 years debut as a public business, um, called Pivot Bio” View on YouTube
Pivot Bio remained a private company as of mid-2026 and did not go public via IPO, SPAC, or direct listing within the 3-4 year predicted window.
In the coming years (on roughly a 5–15 year timescale from 2021), advances in engineering nitrogen-fixing microbes will move far beyond early products like Pivot Bio, enabling broad microbial nitrogen fixation that can significantly reduce or potentially eliminate synthetic fertilizer use and materially reduce agriculture-related greenhouse gas emissions.
“the ability for us to engineer microbes opens up this universe of possibility, where pivot is kind of like, you know, kindergarten level of what's going to happen over the next couple of years where we can now engineer all these microbes to pull nitrogen out of the atmosphere and maybe reduce all fertilizer use and have a huge effect on greenhouse gas resulting from, from, from, from agriculture.” View on YouTube
Nitrogen-fixing microbial technology continued to advance and scale through the 2020s (Pivot Bio and competitors expanded commercially), though a broad transformation significantly reducing synthetic fertilizer use industry-wide has not yet been achieved.
mRNA vaccine/platform technology proven in Covid-19 vaccines will be successfully repurposed in the future for other diseases, potentially including therapeutic applications that directly target and attack certain types of cancer cells.
“even the new mRNA vaccines that were developed for Covid. I mean, it's miraculous, right? And we're going to be able to use that same mRNA technology for other things, other diseases, maybe even to attack cancer cells.” View on YouTube
mRNA technology has been actively pursued for other diseases and cancer therapeutics, with several mRNA-based cancer vaccine candidates advancing through clinical trials by the mid-2020s.
Induced pluripotent stem cell (iPSC)–based stem cell therapies will see very rapid growth and breakthroughs, making stem cell therapy a major, highly active biomedical field over the next couple of decades (approximately 2020s–2040s).
“So IPS now forms the basis for a lot of these stem cell therapy kind of um programs that are underway. And so this is going to be an insane field over the next couple decades.” View on YouTube
iPSC-based stem cell therapy has continued to be a major, highly active biomedical research field with numerous ongoing clinical trials and advances through the mid-2020s.